Abdelaziz, L. A., Taha, H. F., Ali, M. M., Abdelgawad, M. I., & Elwan, A. (2021). Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: A prospective randomized multi-centric Egyptian study. Termedia Publishing House.
Cita Chicago Style (17a ed.)Abdelaziz, Lobna A., Heba F. Taha, Magid M. Ali, Marwa I. Abdelgawad, y Amira Elwan. Tolerability and Outcome of Sunitinib by Giving 4/2 Schedule Versus 2/1 schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study. Termedia Publishing House, 2021.
Cita MLA (8a ed.)Abdelaziz, Lobna A., et al. Tolerability and Outcome of Sunitinib by Giving 4/2 Schedule Versus 2/1 schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study. Termedia Publishing House, 2021.